Related Experiment Video
Updated: Aug 21, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Ezetimibe + simvastatin (Merck/Schering-Plough)
1naflor40@hotmail.com
Abstract:
Merck/Schering-Plough Pharmaceuticals has developed and launched ezetimibe + simvastatin (Vytorin), a fixed combination tablet of Schering-Plough's cholesterol absorption inhibitor ezetimebe (Zetia), and Merck's HMG CoA reductase inhibitor simvastatin (Zocor), for the treatment of hypercholesterolemia. The drug had been launched in Germany and Mexico by April 2004, and, in July 2004, was approved in the US, with expected launch late in 2004.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmaceutical Equivalents
Drug Products: Biologics, Biosimilars and Interchangeables
Dipeptidyl Peptidase 4 Inhibitors
Bioequivalence studies: Biowaivers
